vs

Side-by-side financial comparison of HARVARD BIOSCIENCE INC (HBIO) and Laird Superfood, Inc. (LSF). Click either name above to swap in a different company.

HARVARD BIOSCIENCE INC is the larger business by last-quarter revenue ($23.7M vs $13.3M, roughly 1.8× Laird Superfood, Inc.). HARVARD BIOSCIENCE INC runs the higher net margin — -12.0% vs -13.2%, a 1.2% gap on every dollar of revenue. On growth, Laird Superfood, Inc. posted the faster year-over-year revenue change (15.0% vs -3.3%). Over the past eight quarters, Laird Superfood, Inc.'s revenue compounded faster (16.1% CAGR vs -1.6%).

Harvard Bioscience is a global developer, manufacturer and marketer of life sciences equipment to support research and drug discovery. It is traded on NASDAQ under the stock symbol HBIO.

Laird Superfood, Inc. develops, manufactures and sells a portfolio of plant-based functional superfood products, including premium coffee creamers, hydration blends, nutritional supplements, and plant-powered snacks. It serves health-conscious consumers through direct-to-consumer e-commerce platforms and offline retail partners, mainly operating in the North American market with a focus on sustainably sourced clean ingredients.

HBIO vs LSF — Head-to-Head

Bigger by revenue
HBIO
HBIO
1.8× larger
HBIO
$23.7M
$13.3M
LSF
Growing faster (revenue YoY)
LSF
LSF
+18.4% gap
LSF
15.0%
-3.3%
HBIO
Higher net margin
HBIO
HBIO
1.2% more per $
HBIO
-12.0%
-13.2%
LSF
Faster 2-yr revenue CAGR
LSF
LSF
Annualised
LSF
16.1%
-1.6%
HBIO

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
HBIO
HBIO
LSF
LSF
Revenue
$23.7M
$13.3M
Net Profit
$-2.8M
$-1.8M
Gross Margin
59.7%
34.1%
Operating Margin
7.2%
-13.5%
Net Margin
-12.0%
-13.2%
Revenue YoY
-3.3%
15.0%
Net Profit YoY
-15916.7%
-341.4%
EPS (diluted)
$-0.06

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
HBIO
HBIO
LSF
LSF
Q4 25
$23.7M
$13.3M
Q3 25
$20.6M
$12.9M
Q2 25
$20.4M
$12.0M
Q1 25
$21.8M
$11.7M
Q4 24
$24.6M
$11.6M
Q3 24
$22.0M
$11.8M
Q2 24
$23.1M
$10.0M
Q1 24
$24.5M
$9.9M
Net Profit
HBIO
HBIO
LSF
LSF
Q4 25
$-2.8M
$-1.8M
Q3 25
$-1.2M
$-975.1K
Q2 25
$-2.3M
$-362.2K
Q1 25
$-50.3M
$-156.2K
Q4 24
$18.0K
$-398.4K
Q3 24
$-4.8M
$-166.1K
Q2 24
$-2.9M
$-239.1K
Q1 24
$-4.7M
$-1.0M
Gross Margin
HBIO
HBIO
LSF
LSF
Q4 25
59.7%
34.1%
Q3 25
58.4%
36.5%
Q2 25
56.4%
39.9%
Q1 25
56.0%
41.9%
Q4 24
57.1%
38.6%
Q3 24
58.1%
43.0%
Q2 24
57.2%
41.8%
Q1 24
60.3%
40.0%
Operating Margin
HBIO
HBIO
LSF
LSF
Q4 25
7.2%
-13.5%
Q3 25
1.0%
-7.7%
Q2 25
-4.0%
-3.3%
Q1 25
-228.1%
-1.9%
Q4 24
0.0%
-4.1%
Q3 24
-8.5%
-2.3%
Q2 24
-9.0%
-3.4%
Q1 24
-9.3%
-11.0%
Net Margin
HBIO
HBIO
LSF
LSF
Q4 25
-12.0%
-13.2%
Q3 25
-6.0%
-7.6%
Q2 25
-11.2%
-3.0%
Q1 25
-231.2%
-1.3%
Q4 24
0.1%
-3.4%
Q3 24
-21.9%
-1.4%
Q2 24
-12.7%
-2.4%
Q1 24
-19.1%
-10.3%
EPS (diluted)
HBIO
HBIO
LSF
LSF
Q4 25
$-0.06
Q3 25
$-0.03
Q2 25
$-0.05
Q1 25
$-1.14
Q4 24
$0.01
Q3 24
$-0.11
Q2 24
$-0.07
Q1 24
$-0.11

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
HBIO
HBIO
LSF
LSF
Cash + ST InvestmentsLiquidity on hand
$8.6M
$5.1M
Total DebtLower is stronger
$35.9M
Stockholders' EquityBook value
$13.7M
$11.5M
Total Assets
$80.1M
$19.2M
Debt / EquityLower = less leverage
2.61×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
HBIO
HBIO
LSF
LSF
Q4 25
$8.6M
$5.1M
Q3 25
$6.8M
$5.1M
Q2 25
$7.4M
$3.9M
Q1 25
$5.5M
$7.0M
Q4 24
$4.1M
$8.3M
Q3 24
$4.6M
$7.9M
Q2 24
$4.0M
$7.6M
Q1 24
$4.3M
$7.1M
Total Debt
HBIO
HBIO
LSF
LSF
Q4 25
$35.9M
Q3 25
$34.0M
Q2 25
$34.9M
Q1 25
$36.4M
Q4 24
$37.0M
Q3 24
$34.9M
Q2 24
$35.7M
Q1 24
$35.6M
Stockholders' Equity
HBIO
HBIO
LSF
LSF
Q4 25
$13.7M
$11.5M
Q3 25
$14.1M
$12.8M
Q2 25
$15.7M
$13.4M
Q1 25
$14.8M
$13.3M
Q4 24
$63.3M
$13.2M
Q3 24
$65.3M
$13.1M
Q2 24
$67.2M
$12.6M
Q1 24
$68.8M
$12.7M
Total Assets
HBIO
HBIO
LSF
LSF
Q4 25
$80.1M
$19.2M
Q3 25
$78.0M
$18.9M
Q2 25
$80.1M
$20.4M
Q1 25
$79.8M
$21.5M
Q4 24
$126.6M
$19.3M
Q3 24
$131.2M
$18.8M
Q2 24
$128.9M
$18.0M
Q1 24
$133.2M
$17.6M
Debt / Equity
HBIO
HBIO
LSF
LSF
Q4 25
2.61×
Q3 25
2.41×
Q2 25
2.22×
Q1 25
2.45×
Q4 24
0.58×
Q3 24
0.53×
Q2 24
0.53×
Q1 24
0.52×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
HBIO
HBIO
LSF
LSF
Operating Cash FlowLast quarter
$-96.0K
$68.4K
Free Cash FlowOCF − Capex
$-545.0K
FCF MarginFCF / Revenue
-2.3%
Capex IntensityCapex / Revenue
1.9%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$5.5M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
HBIO
HBIO
LSF
LSF
Q4 25
$-96.0K
$68.4K
Q3 25
$1.1M
$1.2M
Q2 25
$2.8M
$-2.8M
Q1 25
$3.0M
$-1.3M
Q4 24
$1.7M
$339.2K
Q3 24
$-842.0K
$305.8K
Q2 24
$-846.0K
$642.7K
Q1 24
$1.4M
$-422.3K
Free Cash Flow
HBIO
HBIO
LSF
LSF
Q4 25
$-545.0K
Q3 25
$877.0K
Q2 25
$2.7M
Q1 25
$2.5M
Q4 24
$1.4M
Q3 24
$-1.7M
Q2 24
$-1.7M
Q1 24
$758.0K
FCF Margin
HBIO
HBIO
LSF
LSF
Q4 25
-2.3%
Q3 25
4.3%
Q2 25
13.0%
Q1 25
11.4%
Q4 24
5.8%
Q3 24
-7.8%
Q2 24
-7.2%
Q1 24
3.1%
Capex Intensity
HBIO
HBIO
LSF
LSF
Q4 25
1.9%
Q3 25
1.0%
Q2 25
0.4%
Q1 25
2.4%
Q4 24
1.2%
Q3 24
4.0%
Q2 24
3.5%
Q1 24
2.6%
Cash Conversion
HBIO
HBIO
LSF
LSF
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
95.83×
Q3 24
Q2 24
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

HBIO
HBIO

Instruments Equipment Software And Accessories$21.6M91%
Service Maintenance And Warranty Contracts$2.1M9%

LSF
LSF

Wholesale$7.0M52%
Coffee Tea And Hot Chocolate Products$4.4M33%
Hydration And Beverage Enhancing Supplements$1.6M12%
Other$352.6K3%

Related Comparisons